Xeris Biopharma Reports Cortisol Normalization With Recorlev in Cushing's Syndrome Case Study
Xeris Biopharma announced a Recorlev case study showing normalized cortisol levels with improved cardiometabolic health in a patient with difficult-to-control diabetes. The case study is scheduled for presentation at the Cardiometabolic Health Congress on October 15-16, 2026. Gvoke research presented October 9, 2026, f